Synonyms: compound 39 [PMID: 35652647] | MT-3995 | MT3995
Compound class:
Synthetic organic
Comment: Apararenone (MT-3995) is a selective and potent non-steroidal mineralocorticoid receptor (MR) antagonist [1]. It was developed to counteract MR-induced hypertension and organ damage in diseases including diabetic nephropathy and NASH.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Apararenone (MT-3995) is a phase 2 clinical candidate. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02517320 | Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy | Phase 2 Interventional | Mitsubishi Tanabe Pharma Corporation | 2 | |
NCT02923154 | Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) | Phase 2 Interventional | Mitsubishi Tanabe Pharma Corporation |